Creative Planning
AIMT

Creative Planning’s Aimmune Therapeutics AIMT Stock Holding History

Creative Planning’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,720
Closed -$56K – 4173
2017
Q2 		$56K Buy
+2,720
New +$51.9K ﹤0.01% 2442

Other funds holding AIMT

FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Creative Planning's AIMT Position: Q3 2017 in Review

Creative Planning sold out of Aimmune Therapeutics (AIMT) in Q3 2017, closing a stake of 2,720 shares — an estimated $56K sold.

Creative Planning first reported a position in AIMT in Q2 2017 and held it in 1 quarter. The position peaked at $56K in Q2 2017. 100 funds tracked by Wall St. Rank hold AIMT as of Q3 2017.

  • Creative Planning reported no remaining Aimmune Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Creative Planning sold 2,720 Aimmune Therapeutics shares in Q3 2017, an estimated $56K.
  • Creative Planning first reported a position in Aimmune Therapeutics in Q2 2017 and held it in 1 quarter.
  • Creative Planning's Aimmune Therapeutics position peaked at $56K in Q2 2017.
  • 100 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.